DANSAC-RCT: Fosaprepitant in patients with advanced cancer not receiving chemotherapy or irradiation; A multicenter, randomized, double-blind, placebo-controlled study.
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Nausea; Vomiting
- Focus Therapeutic Use
- Acronyms DANSAC-RCT
- 14 Sep 2017 Status changed from recruiting to discontinued.
- 08 Mar 2016 New trial record